Manager × security

Pivotal bioVenture Partners Investment Advisor LLC ARQT holdings history

Who else holds this security? →

ARCUTIS BIOTHERAPEUTICS INC · CUSIP 03969K108 · CIK 1844645

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Pivotal bioVenture Partners Investment Advisor LLC reported 1.27M ARQT (shares), valued at $33.18M, or 10.78% of its reported non-derivative portfolio. Filed 2026-08-13.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
10.78%
Shares
1.27M
1,265,283
Reported value
$33.18M
USD

Shares decreased 6.68%; reported value increased 3.85%, and weight changed -0.64 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 202610.78%1,265,283SEC filing ↗Filed Aug 13, 2026
Q1 202611.42%1,355,892SEC filing ↗Filed May 14, 2026
Q4 202515.34%1,366,624SEC filing ↗Filed Feb 13, 2026
Q3 202523.11%2,120,508SEC filing ↗Filed Nov 13, 2025
Q2 202518.43%2,120,508SEC filing ↗Filed Aug 13, 2025
Q1 202526.84%2,120,508SEC filing ↗Filed May 14, 2025
Q4 202419.95%2,120,508SEC filing ↗Filed Feb 13, 2025
Q3 202411.71%2,120,508SEC filing ↗Filed Nov 13, 2024
Q2 202414.59%2,041,108SEC filing ↗Filed Aug 13, 2024
Q1 202412.92%2,028,008SEC filing ↗Filed May 14, 2024
Q4 20231.56%1,910,009SEC filing ↗Filed Feb 13, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20231.56%1,910,009$6.17MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Feb 13, 2024
Q1 202412.92%2,028,008$20.10MShares increased 6.18%; reported value increased 225.77%, and weight changed +11.36 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 14, 2024
Q2 202414.59%2,041,108$18.98MShares increased 0.65%; reported value decreased 5.55%, and weight changed +1.67 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 13, 2024
Q3 202411.71%2,120,508$19.72MShares increased 3.89%; reported value increased 3.89%, and weight changed -2.88 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 13, 2024
Q4 202419.95%2,120,508$29.54MShares unchanged; reported value increased 49.78%, and weight changed +8.24 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 13, 2025
Q1 202526.84%2,120,508$33.16MShares unchanged; reported value increased 12.28%, and weight changed +6.89 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 14, 2025
Q2 202518.43%2,120,508$29.73MShares unchanged; reported value decreased 10.36%, and weight changed -8.41 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 13, 2025
Q3 202523.11%2,120,508$39.97MShares unchanged; reported value increased 34.45%, and weight changed +4.68 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 13, 2025
Q4 202515.34%1,366,624$39.69MShares decreased 35.55%; reported value decreased 0.71%, and weight changed -7.77 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 13, 2026
Q1 202611.42%1,355,892$31.94MShares decreased 0.79%; reported value decreased 19.51%, and weight changed -3.92 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 14, 2026
Q2 202610.78%1,265,283$33.18MShares decreased 6.68%; reported value increased 3.85%, and weight changed -0.64 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 13, 2026
Pivotal bioVenture Partners Investment Advisor LLC · ARCUTIS BIOTHERAPEUTICS INC

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1844645","quarter":"2026Q2","cusip":"03969K108"}

get_institutional_manager_history
{"cik":"1844645","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.